+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Madrigal Pharmaceuticals Inc (MDGL) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 55 Pages
  • April 2023
  • GlobalData
  • ID: 1322625
Madrigal Pharmaceuticals Inc (MDGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Madrigal Pharmaceuticals Inc (Madrigal), formerly Synta Pharmaceuticals Corp, is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel drugs for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, resmetirom (MGL-3196), is a proprietary, liver-directed, selective thyroid hormone receptor beta (THR-beta) agonist that can potentially help treat several diseases with high unmet medical need. The company is developing resmetirom for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), associated dyslipidemias and familial hypercholesterolemia (FH). The company is also developing MGL-3745 (THR-beta agonist), a preclinical compound that has thyroid receptor selectivity similar to that of MGL-3196. Madrigal is headquartered in West Conshohocken, Pennsylvania, the US.

Madrigal Pharmaceuticals Inc Key Recent Developments

  • Feb 23, 2023: Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
  • Nov 03, 2022: Madrigal Pharmaceuticals provides an overview of upcoming resmetirom data presentations and reports 2022 third quarter financial results
  • Aug 04, 2022: Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
  • Jun 06, 2022: Madrigal Pharmaceuticals supports international NASH Day on June 9

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Madrigal Pharmaceuticals Inc - Key Facts
  • Madrigal Pharmaceuticals Inc - Key Employees
  • Madrigal Pharmaceuticals Inc - Key Employee Biographies
  • Madrigal Pharmaceuticals Inc - Major Products and Services
  • Madrigal Pharmaceuticals Inc - History
  • Madrigal Pharmaceuticals Inc - Company Statement
  • Madrigal Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Madrigal Pharmaceuticals Inc - Business Description
  • R&D Overview
  • Madrigal Pharmaceuticals Inc - Corporate Strategy
  • Madrigal Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Madrigal Pharmaceuticals Inc - Strengths
  • Madrigal Pharmaceuticals Inc - Weaknesses
  • Madrigal Pharmaceuticals Inc - Opportunities
  • Madrigal Pharmaceuticals Inc - Threats
  • Madrigal Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Madrigal Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 23, 2023: Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
  • Nov 03, 2022: Madrigal Pharmaceuticals provides an overview of upcoming resmetirom data presentations and reports 2022 third quarter financial results
  • Aug 04, 2022: Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
  • Jun 06, 2022: Madrigal Pharmaceuticals supports international NASH Day on June 9
  • May 09, 2022: Madrigal Pharmaceuticals provides clinical and business updates and reports 2022 first quarter financial results
  • Apr 28, 2022: Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
  • Feb 24, 2022: Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
  • Jan 10, 2022: Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Madrigal Pharmaceuticals Inc, Key Facts
  • Madrigal Pharmaceuticals Inc, Key Employees
  • Madrigal Pharmaceuticals Inc, Key Employee Biographies
  • Madrigal Pharmaceuticals Inc, Major Products and Services
  • Madrigal Pharmaceuticals Inc, History
  • Madrigal Pharmaceuticals Inc, Subsidiaries
  • Madrigal Pharmaceuticals Inc, Key Competitors
  • Madrigal Pharmaceuticals Inc, Ratios based on current share price
  • Madrigal Pharmaceuticals Inc, Annual Ratios
  • Madrigal Pharmaceuticals Inc, Interim Ratios
  • Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Madrigal Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Madrigal Pharmaceuticals Inc, Performance Chart (2018 - 2022)
  • Madrigal Pharmaceuticals Inc, Ratio Charts
  • Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Viking Therapeutics Inc
  • Pfizer Inc
  • Novo Nordisk AS
  • Novartis AG
  • NGM Biopharmaceuticals Inc
  • Mirum Pharmaceuticals Inc
  • Gilead Sciences Inc
  • Genfit Corp
  • Galectin Therapeutics Inc
  • Bristol-Myers Squibb & Gilead Sciences LLC
  • Boehringer Ingelheim International GmbH
  • Astrazeneca, 297 North Bernardo Avenue, Mountain View, California, United States
  • Allergan Ltd
  • Akero Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk AS
  • Gilead Sciences Inc
  • Novartis AG
  • Akero Therapeutics Inc
  • NGM Biopharmaceuticals Inc
  • Allergan Ltd
  • Genfit Corp
  • Astrazeneca, 297 North Bernardo Avenue, Mountain View, California, United States
  • Galectin Therapeutics Inc
  • Bristol-Myers Squibb & Gilead Sciences LLC
  • Mirum Pharmaceuticals Inc
  • Viking Therapeutics Inc
  • Pfizer Inc